From Model to Moving Target: The Evolution of Cancer Cell Lines in Culture

Have you ever found yourself staring at a Western blot or a qPCR readout, wondering why the “clean” results you obtained last month have suddenly disappeared? After checking the buffers, calibrating the pipettes, and questioning the antibody, it is easy to conclude that the problem lies in technique. But in cancer research, another possibility deserves equal attention: the biology of the model itself may have changed. Cancer cell lines are not static reagents. In many settings, they are genomically unstable and capable of substantial phenotypic drift during prolonged culture, with passage history, culture conditions, and clonal selection all influencing experimental behavior. Studies comparing independently maintained batches and derivative strains of commonly used cell lines have shown marked differences in genomic content, gene expression, and response patterns, underscoring that apparently “identical” cultures may not remain biologically equivalent over time. At the same time, this instability is not universal, and some model systems are considerably more stable than others. This article examines how genomic and transcriptomic drift can emerge during routine propagation of cancer cell lines, why that drift matters for reproducibility, and how researchers can better account for it in experimental design.

Defining Clonal Drift in the Dish

In the context of cell culture, clonal drift refers to the gradual accumulation of genetic and phenotypic changes within a cell population over successive passages. Importantly, many commonly used cancer cell lines are not truly clonal but instead consist of heterogeneous subpopulations with distinct mutational and transcriptional profiles. During routine passaging, these subpopulations may be differentially favored under in vitro conditions, introducing selective pressures that can shift the overall composition of the culture over time.

As a result, subclones that are better adapted to artificial culture conditions, such as growth on rigid plastic surfaces or survival in defined media, may become enriched. Over extended passaging, this process can lead to measurable divergence from the original cellular state, including changes in gene expression, signaling behavior, and experimental response. However, the extent and rate of such drift can vary substantially depending on the cell line, culture conditions, and duration in vitro.

The Hierarchy

The extent of phenotypic and genomic drift in vitro is not uniform across model systems. Primary cells, which retain intact cell cycle checkpoints and a limited replicative lifespan (the Hayflick limit), are generally less permissive to long-term accumulation of genetic alterations, although they can still undergo selection and phenotypic changes during short-term culture.

In contrast, immortalized cell lines, often generated through the introduction of factors such as hTERT or viral oncogenes, bypass replicative senescence and can be maintained for extended periods. While some of these lines retain relatively stable karyotypes, others may acquire genetic and transcriptional changes over time, depending on culture conditions and passage history.

Cancer cell lines frequently exhibit higher baseline genomic instability, including aneuploidy and ongoing chromosomal alterations, which can increase their susceptibility to clonal selection and drift during in vitro propagation. As a result, the rate and extent of divergence from the original cellular state may be more pronounced in certain cancer models, posing important considerations for experimental reproducibility and interpretation.

The Mutator Phenotype in Cancer

Cancer cell lines are often more susceptible to genomic and phenotypic drift due to underlying features of genomic instability. In many cases, tumors exhibit a “mutator phenotype,” characterized by elevated mutation rates and impaired mechanisms for maintaining genomic integrity. For example, alterations in key regulatory pathways such as p53 can reduce the ability of cells to appropriately respond to DNA damage through cell cycle arrest, repair, senescence, or apoptosis.

In addition, many cancer cell lines are aneuploid, harboring abnormal chromosome numbers and structural rearrangements. This chromosomal instability can result in ongoing gains or losses of genomic material across cell divisions, contributing to substantial intra-population heterogeneity.

From an evolutionary perspective, this increased genetic diversity provides a substrate for selection under in vitro conditions. As a result, subpopulations with growth or survival advantages in culture may become enriched over time, potentially leading to divergence from the original tumor-derived state.

The 3D Paradox: Increased Complexity, New Sources of Variability

The transition from traditional 2D culture systems to 3D models, such as spheroids, organoids, and bioprinted tissues, has been driven by the goal of better recapitulating in vivo architecture and microenvironmental signaling, as these systems can reproduce key structural and functional features of native tissues. Organoids, in particular, form complex, self-organized structures with inherent cellular heterogeneity, enabling more physiologically relevant modeling of disease processes.

However, increasing structural complexity does not eliminate phenotypic variability. Instead, it introduces additional layers of environmental heterogeneity that can influence cellular behavior over time.

Microenvironmental Gradients as Selective Pressures

Unlike monolayer cultures, 3D systems inherently generate gradients in oxygen and nutrient availability due to diffusion limitations within multicellular structures. Cells located at the periphery may experience conditions distinct from those in the core, which can be relatively hypoxic or nutrient limited. These gradients can influence proliferation, survival, and gene expression, potentially favoring subpopulations better adapted to these microenvironments.

Matrix and Culture-Dependent Variability

Many 3D systems rely on extracellular matrix substitutes such as Matrigel, whose undefined composition and batch-to-batch variability can influence experimental reproducibility and cellular behavior. In addition, differences in matrix composition, growth factor supplementation, and culture conditions can lead to significant variability across experiments.

Temporal Variability in Advanced Models

Although 3D models can retain key genetic features of the original tumor, including major driver mutations, functional properties such as drug response and signaling behavior can evolve over time in culture . These observations highlight that even advanced in vitro systems remain dynamic rather than static representations of disease.

What happens to organ tropic nature of metastatic cancer cells in a dish?

Emerging evidence suggests that metastatic phenotypes are not entirely cell-intrinsic but are strongly influenced by the organ-specific microenvironment. Several studies have demonstrated that metastatic traits induced within a given niche can be partially reversible upon removal from that environment. For example, loss of PTEN expression in brain metastases has been shown to be mediated by astrocyte-derived signals and restored following ex vivo culture, highlighting the dynamic and reversible nature of microenvironment-driven phenotypes (Zhang et al., Nature, 2015). Similarly, bone microenvironment–induced transcriptional and stem-like programs have been reported to exhibit plasticity when cells are removed from the metastatic niche (Cell, 2021).

In this context, it is plausible that prolonged in vitro culture under standard 2D conditions, lacking organ-specific biochemical and mechanical cues ,may attenuate organ-tropic features over time. While direct evidence for complete loss of organ tropism is limited, these observations support the possibility that certain niche-dependent transcriptional or functional characteristics may diminish during extended passaging, potentially impacting the physiological relevance of long-term cultured metastatic cell lines.

What Do Cell Repositories Do to Minimize Drift?

To reduce the risk of genetic and phenotypic drift, major cell repositories such as ATCC implement standardized cell banking strategies designed to limit the number of population doublings prior to distribution. These systems aim to preserve early-passage characteristics and improve reproducibility across laboratories.

1.   Tiered Cell Banking Systems: Most repositories use a hierarchical banking structure consisting of a Master Cell Bank (MCB) and a Working Cell Bank (WCB).

2.     Master Cell Bank (MCB): Following initial characterization, cells are expanded for a limited number of passages and cryopreserved as a long-term reference stock.

3.   Working Cell Bank (WCB): A vial from the MCB is thawed and expanded to generate working stocks distributed to researchers. When these stocks are depleted, new batches are generated from the original MCB, thereby limiting cumulative culture-induced changes.

4.   Identity and Quality Control Measures: In addition to standard authentication methods such as STR profiling, repositories may employ additional characterization approaches to assess genomic integrity and consistency.

5.   Genomic profiling (e.g., SNP arrays or karyotyping):These methods can detect large-scale genomic alterations, including copy number variations, that may not be captured by identity testing alone.

6.   Phenotypic characterization:Key features such as morphology, growth rate, and expression of lineage-specific markers may be evaluated during initial characterization and, in some cases, during batch validation.

Limitations and Downstream Considerations

While these practices help preserve early-passage characteristics, the cells received by researchers still represent a starting population rather than a static biological entity. Once cultured under laboratory-specific conditions, including media composition, passage strategy, and environmental factors, cell populations may continue to evolve over time.

A Shared Path Forward: Elevating Our Standards Together

If the data from the last few years has shown us anything, it is that cancer cell lines-whether in 2D or 3D, are dynamic, living systems rather than static reagents. Recognizing the "reproducibility crisis" as a natural byproduct of biological evolution allows us to move away from a culture of technical doubt and toward a more nuanced era of discovery. By working together to update our workflows, we can protect both the integrity of our data and the researchers who produce it.

1. Enhancing Our Validation Toolkit

While STR profiling remains an essential first step for confirming a cell line’s identity, we have the opportunity to supplement it with more functional insights. Integrating "Transcriptomic Snapshots",such as low-cost RNA-seq or targeted gene panels, at various passage intervals can help us stay aligned with our biological targets. Understanding if a cell’s "metabolic engine" has shifted before starting a major experiment helps ensure that our results remain as representative as possible.

2. Prioritizing Context in Our Reporting

Small details in our methods sections can offer immense value to the community. Simply including the exact passage number for each key experiment or figure helps other labs replicate our findings with greater accuracy. This transparency acknowledges that a cell at Passage 3 is a different biological entity than one at Passage 20, turning a potential variable into a valuable piece of data.

3. Fostering a Culture of Biological Curiosity

Perhaps the most meaningful shift we can make is a cultural one. When experimental results begin to drift, it serves as an invitation to ask: "How has this population evolved?" rather than searching for a technical error. By acknowledging that cancer is, by definition, an evolving system, we can shift the conversation toward a deeper understanding of clonal dynamics.

So…

The next time your data behaves unexpectedly, take a moment to consider that you are working with one of the most complex systems in nature. You are not just following a protocol, you are observing biology as it adapts and evolves in real time. By recognizing and accounting for clonal drift, we can move toward a more resilient, thoughtful, and ultimately more accurate approach to cancer research.

References

1.  Almeida, J. L., Cole, K. D., & Plant, A. L. (2016). Standards for cell line authentication and beyond. PLOS Biology, 14(6), e1002476. https://doi.org/10.1371/journal.pbio.1002476

2.  Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., Nag, A., Kugener, G., Cimini, B., Tsvetkov, P., Maruvka, Y. E., O’Rourke, R., Garrity, A., Tubelli, A. A., Bandopadhayay, P., ... Golub, T. R. (2018). Genetic and transcriptional evolution alters cancer cell line drug response. Nature, 560(7718), 325–330. https://doi.org/10.1038/s41586-018-0409-3

3.   Landry, J. J., Pyl, P. T., Rausch, T., Zichner, T., Tekkedil, M. M., Stütz, A. M., Jauch, A., Aiyar, R. S., Pau, G., Delhomme, N., Gagneur, J., Korbel, J. O., Huber, W., & Steinmetz, L. M. (2013). The genomic and transcriptomic landscape of a HeLa cell line. G3: Genes, Genomes, Genetics, 3(8), 1213–1224. https://doi.org/10.1534/g3.113.005777

4.  Liu, Y., Mi, Y., Mueller, T., Kreibich, S., Williams, E. G., Van Drogen, A., Borel, C., Frank, M., Germain, P. L., Bludau, I., Mehnert, M., Seifert, M., Emmenlauer, M., Sorg, I., Bezrukov, F., Bena, F. S., Zhou, H., Dehio, C., Testa, G., ... Aebersold, R. (2019). Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nature Biotechnology, 37(3), 314–322. https://doi.org/10.1038/s41587-019-0037-y

5. Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W. C., Li, P., Li, M., Wang, X., Zhang, C., Wang, H., Ellis, K., Cheerathodi, M., McCarty, J. H., Palmieri, D., Saunus, J., Lakhani, S., Huang, S., Sahin, A. A., Aldape, K. D., … Yu, D. (2015). Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature, 527(7576), 100–104. https://doi.org/10.1038/nature15376

6. Drost, J., & Clevers, H. (2018). Organoids in cancer research. Nature reviews. Cancer, 18(7), 407–418. https://doi.org/10.1038/s41568-018-0007-6

7.  Bado, I. L., Zhang, W., Hu, J., Xu, Z., Wang, H., Sarkar, P., Li, L., Wan, Y. W., Liu, J., Wu, W., Lo, H. C., Kim, I. S., Singh, S., Janghorban, M., Muscarella, A. M., Goldstein, A., Singh, P., Jeong, H. H., Liu, C., Schiff, R., … Zhang, X. H. (2021). The bone microenvironment increases phenotypic plasticity of ER⁺ breast cancer cells. Developmental cell, 56(8), 1100–1117.e9. https://doi.org/10.1016/j.devcel.2021.03.008